ArticleJMA journal2025
Change in Breast Cancer Screening Participation during COVID-19 Based on the 2019 and 2022 Comprehensive Survey of Living Conditions in Japan.
Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The breast cancer screening rate declined worldwide during the COVID-19 pandemic. This cross-sectional study examined the changes in breast cancer screening participation rates in Japan before and during the pandemic and identified subgroups with a larger decline. Methods: We used data from a 2019 survey evaluating 2017-2018 (pre-pandemic) and a 2022 survey evaluating 2020-2021 (during the pandemic) in the Comprehensive Survey of Living Conditions to describe the breast cancer screening rates by screening settings among women aged 40-74 years. We calculated the changes in the overall participation rate and by subgroup with and without adjustment for other variables (i.e., age, living area, educational level, and health insurance). Results: The participation rates in breast cancer screening in 2017-2018 and 2020-2021 were 48.3% (51,428/106,446, municipality-based 18.7%, worksite-based 17.0%, and others 12.6%) and 47.1% (45,006/95,610, municipality-based 17.2%, worksite-based 17.5%, and others 12.4%), respectively. The crude difference from 2017-2018 to 2020-2021 was -1.2% (95% confidence interval [CI], -1.7 to -0.8), and the adjusted difference was -1.7% (-2.2 to -1.4). By subgroup, the adjusted difference was the largest in the 45-49 age subgroup (-2.2% [-3.3 to -1.1]) among the age subgroups, in the town/village subgroup (-2.4% [-3.6 to -1.2]) among the living area subgroups, in the high school subgroup (-1.8% [-2.4 to -1.2]) and vocational school/junior or technical college subgroup (-1.8% [-2.6 to -1.0]) among the educational level subgroups, and in the employee insurance (dependent person) subgroup (-2.5% [-3.3 to -1.7]) among the health insurance subgroups. Conclusions: The breast cancer screening participation rates decreased during the pandemic in Japan, with some variations by subgroup. For the screening setting, the participation rate of the municipality-based screening decreased, while that of the worksite-based screening increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.